COMP <GO>
AMRN vs CAMP // RSI-14 & 200D SMA MOMENTUM
Amarin Corporation plc (NASDAQ) VS. CAMP4 Therapeutics Corporation (NASDAQ) • 15-METRIC TALLY: AMRN 6
— CAMP 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: CAMP
LAST: $12.13 (+0.17%) • MKT CAP: $249.9M
rsi-technicals
47.1
LAST: $3.78 (-4.67%) • MKT CAP: $248.5M
rsi-technicals
58.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMRN VS. CAMP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMRN | CAMP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.60% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -12.20% | -35.00% | +22.80 | AMRN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.56% | -12.19% | +14.75 | AMRN | /fcf-yield <GO> |
| Operating Margin | -23.50% | -60.00% | +36.50 | AMRN | /operating-margins <GO> |
| Net Profit Margin | -18.20% | -60.00% | +41.80 | AMRN | /net-margins <GO> |
| Revenue Growth (YoY) | -6.50% | 180.00% | -186.50 | CAMP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.20 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 3/9 | +3.00 | AMRN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 47.1 | 58.4 | -11.30 | CAMP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $249.9M | $248.5M | $1.4M | AMRN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMRN REV | CAMP REV | AMRN GROSS % | CAMP GROSS % | AMRN FCF | CAMP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $213.6M | $3.5M | 56.6% | — | $6.7M | -$29.8M |
| FY 2024 | $228.6M | $652.0K | 35.6% | — | -$31.0M | -$46.0M |
| FY 2023 | $306.9M | $350.0K | — | — | $6.9M | -$44.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMRN // BETA —
CAMP // BETA —